The Alpha Journal — Men’s Health Reporting

Viagra (sildenafil) remains the clear first-line choice for most men with erectile dysfunction — guideline-endorsed, fast-acting, and backed by decades of randomized trial data.

Daily tadalafil at 5 mg produces modestly higher rates of successful intercourse than on-demand dosing and is the only PDE5 inhibitor regimen FDA-approved for both erectile dysfunction and lower urinary tract symptoms from benign prostatic hyperplasia.

Stendra (avanafil) wins on speed; Cialis (tadalafil) wins on flexibility and cost. For most men, those two sentences settle the choice — but the details matter enough to read past them.

Sildenafil not working doesn't mean you're out of options — it often means you haven't found the right option yet. Research consistently shows that 25–35% of men report inadequate response to Viagra, but a large fraction of those are fixable with better technique, a different…

Tadalafil lasts significantly longer than sildenafil — up to 36 hours versus 4–6 hours — and that difference comes down to a single pharmacokinetic fact: tadalafil's half-life is roughly 17.5 hours compared to sildenafil's 3–5 hours.

Tadalafil (Cialis) and vardenafil (Levitra) are both proven PDE5 inhibitors, but they serve different sexual lifestyles — and choosing between them comes down to how often you have sex, whether you also have urinary symptoms, and how much you want to plan around a pill.

For daily ED therapy, Cialis (tadalafil) 2.5–5 mg once daily is the clear evidence-based choice — it's the only PDE5 inhibitor with FDA approval specifically for that indication.

Two sessions a week—totaling roughly 30–60 minutes—appears to be the dose at which resistance training delivers its largest mortality benefit. Beyond that threshold, returns diminish fast; below it, you're leaving meaningful protection on the table.

Several legitimate non-prescription approaches to erectile dysfunction are backed by controlled trial data — but the gap between evidence and marketing claims is wide. Here's what the research actually supports, ranked by strength of evidence.

Low-intensity shockwave therapy (LI-ESWT) produces real, measurable improvements in erectile function for men with mild-to-moderate vasculogenic ED — but the gains are modest, durability past 12 months is uncertain, and the FDA still classifies it as investigational.

Tadalafil is the best-fit ED medication for most men over 50—but "best" depends heavily on your cardiovascular profile, other medications, and whether you want a pill you take daily or one you time around sex. Here's what the evidence actually supports.

Tadalafil wins on patient preference and flexibility; sildenafil wins on cost. Neither drug is objectively superior in raw erectile outcomes — the right choice depends on how you have sex, what you can afford, and which side effects you can tolerate.